Bisphosphonates inhibit osteoclast activity to slow bone resorption and increase bone density, but may not build healthy bone and can lead to atypical femur fractures. — Whalespan
Bisphosphonates inhibit osteoclast activity to slow bone resorption and increase bone density, but may not build healthy bone and can lead to atypical femur fractures.
⚠ High risk
We can't find evidence that holds up here. Proponents are reasoning from mechanism or analogy rather than direct human data, and the most credible skeptics raise objections we can't dismiss.
✕NOTSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“the osteoclasts get inhibited by some of the pharmacotherapies the Fosamax boniva is that list phosphonates that slow down and quote-unquote build bone density but it's not necessarily building great bone and so it's building denser bone but there's concerns that there may be fault lines in the bone that it may not necessarily be more torsionally resistant it's not more tension resistance so you see tension sided failure of bone with prolonged use of bisphosphonates and so those are some of the atypical femur fractures that you see people get foot fractures with this”